| Literature DB >> 30214457 |
Carina Agostinho Rodrigues1, Paloma Freire Dos Santos1, Marcela Oliveira Legramanti da Costa1, Thais Fernanda Amorim Pavani1, Patrícia Xander2, Mariana Marques Geraldo2, Ana Mengarda3, Josué de Moraes3, Daniela Gonçales Galasse Rando1.
Abstract
BACKGROUND: There is still a need for new alternatives in pharmacological therapy for neglected diseases, as the drugs available show high toxicity and parenteral administration. That is the case for the treatment of leishmaniasis, particularly to the cutaneous clinical form of the disease. In this study, we present the synthesis and biological screening of eight 4-phenyl-1,3-thiazol-2-amines assayed against Leishmania amazonensis. Herein we propose that these compounds are good starting points for the search of new antileishmanial drugs by demonstrating some of the structural aspects which could interfere with the observed activity, as well as suggesting potential macromolecular targets.Entities:
Keywords: 2-aminothiazoles; Antikinetoplastids; Antileishmanial; Cutaneous; Target fishing
Year: 2018 PMID: 30214457 PMCID: PMC6131760 DOI: 10.1186/s40409-018-0163-x
Source DB: PubMed Journal: J Venom Anim Toxins Incl Trop Dis ISSN: 1678-9180
The 4-Phenyl-1,3-thiazol-4-amines series
| Compound | R | CLogPa | MRb | Yield % |
|---|---|---|---|---|
| 01 | H | 2.61 | 50.20 | 61 |
| 02 | 4-CH3 | 3.07 | 55.25 | 72 |
| 03 | 4-CH2CH3 | 3.47 | 59.85 | 59 |
| 04 | 3,4-Cl | 3.64 | 59.81 | 53 |
| 05 | 4-CF3 | 3.49 | 56.18 | 18 |
| 06 | 4-C(CH3)3 | 4.23 | 68.87 | 27 |
| 07 | 4-OH | 2.32 | 52.19 | 47 |
| 08 | 4-Cl | 3.12 | 55.01 | 67 |
(a) Calculated n-Octanol/Water Partition Coefficient; (b) Molar Refractivity
IC50 values against L. amazonensis promastigotes and the cytotoxicity assay results, expressed as CC50 values
| Compound | IC50 (μM) | pIC50 | CC50 (μM) THP1 cellsa) | SI | CC50 (μM) L929 cellsb) | SI | CC50 (μM) VERO cellsc) | SI |
|---|---|---|---|---|---|---|---|---|
| 1 | 957.56 | 3.02 | 143.57 | 0.15 | 198.26 | 0.20 | 710.06 | 0.74 |
| 2 | 107.68 | 3.97 | 135.40 | 1.26 | 159.52 | 1.48 | 657.51 | 6.11 |
| 3 | 46.63 | 4.33 | 117.27 | 2.51 | 95.45 | 2.05 | 1217.5 | 26.11 |
| 4 | 53.12 | 4.27 | 84.65 | 1.59 | 121.12 | 2.28 | 255.03 | 4.80 |
| 5 | 53.37 | 4.27 | 92.21 | 1.73 | 106.08 | 2.00 | 511.76 | 9.59 |
| 6 | 20.78 | 4.68 | 45.73 | 2.20 | 27.07 | 1.30 | 118.17 | 5.69 |
| 7 | inactive | inactive | inactive | ND | Inactive | ND | 651.29 | ND |
| 8 | 115.95 | 3.94 | 82.15 | 0.70 | 115.06 | 0.99 | 595.94 | 5.14 |
| Amphotericin B | 16.23 | – | ND | – | ND | – | ND | – |
| Pentamidine | 10.76 | – | ND | – | ND | – | ND | – |
(a) THP1 cells: human monocytic cell line derived from acute monocytic leukemia patients; (b) L929 cells: fibroblasts from subcutaneous connective tissue; c) Vero cells: kidney epithelial cells extracted from African green monkeys. IC50: Half-maximal inhibitory concentration on promastigotes; pIC50: Half-maximal inhibitory concentration in log units; CC50: Half cytotoxic concentration; SI: Selectivity Indexes, ND: Not determined. pIC50 calculates as pIC50 = −log10 (IC50)
Pharmmapper results
| Target | PDB Code | Ligand Compounds | Max z’score valuea | Function |
|---|---|---|---|---|
| S-Methyl-5-thioadenosine phosphorylase | 1CG6 | All derivatives | 3.69 | Nucleotide transport and metabolism |
| Adenosine deaminase | 1 V79/1 V89 | All but compound | 4.72 | Nucleotide transport and metabolism |
| UvrABC System Protein B | 1C40 | All but compound | 3.59 | Replication, recombination, and repair |
| Dihydrofolate reductase | 1IA2 | All but compound | 3.12 | Coenzyme transport and metabolism |
| Queuine t-RNA-ribosyltransferase | 1Q66 | All but compounds | 3.02 | Translation, ribosomal structure and biogenesis |
(a) among all compounds tested
BLAST results for Leishmania sp protein sequences producing significant alignment with human S-methyl-5-thioadenosine phosphorylase
| Target | Max Score | Total Score | Query Cover (%) | E value | Identity (%) |
|---|---|---|---|---|---|
| Putative methylthioadenosine phosphorylase [ | 182 | 182 | 87 | 2e-55 | 38 |
| Putative methylthioadenosine phosphorylase [ | 180 | 180 | 87 | 1e-54 | 38 |
| Putative methylthioadenosine phosphorylase [ | 182 | 182 | 95 | 3e-55 | 37 |
| Putative methylthioadenosine phosphorylase [ | 182 | 182 | 95 | 2e-55 | 37 |
| Putative methylthioadenosine phosphorylase [ | 179 | 179 | 95 | 2e-54 | 37 |
| Putative methylthioadenosine phosphorylase [ | 179 | 179 | 95 | 2e-54 | 37 |
Fig. 1Docking at the S-methyl-5-thioadenosine phosphorylase. (a) Co-crystallized ligand. (b) Compound 6 docked at the active site. Blue dashed lines: pi-stacking interactions; black dashed lines: hydrogen bonds (For color version, please access the online version of the article)
Fig. 2(a) Human and (b) L. Mexicana S-methyl-5-thioadenosine phosphorylase binding site alignment